GlassScriptPhysician profile
Carrielle Kemp
NPI 1932650413
$827.70
in general payments reported to CMS, 2019-2025
23 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.23 · 2023: $247 · 2024: $329 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $123.26 | 2023-2025 | Darzalex, Rybrevant, Tecvayli |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Genentech USA, INC. | $64.47 | 2024-2025 | Tecentriq, Tecentriq Hybreza |
| Coherus Oncology, INC. | $63.19 | 2024 | |
| Tersera Therapeutics LLC | $54.67 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $49.52 | 2023 | Enhertu |
| Pfizer INC. | $41.25 | 2023-2025 | |
| Axsome Therapeutics, INC. | $34.44 | 2024 | Auvelity |
| Alkermes, INC. | $24.59 | 2024 | Lybalvi |
| Ipsen Biopharmaceuticals, INC | $23.99 | 2023 | Somatuline Depot, Onivyde |
| Immunogen, INC. | $22.02 | 2023 | Elahere |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.52 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.43 | 2025 | Lynozyfic |
| Astrazeneca Pharmaceuticals LP | $20.44 | 2025 | |
| Merck Sharp & Dohme LLC | $19.89 | 2025 | Keytruda, Keytruda Qlex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $19.66 | 2023 | Epkinly |
| Janssen Scientific Affairs, LLC | $19.66 | 2024 | Spravato |
| Abbvie INC. | $18.92 | 2024 | |
| Pharmaand Gmbh | $18.55 | 2025 | Rubraca |
| Genzyme Corporation | $17.50 | 2023 | |
| Tolmar, INC. | $16.77 | 2025 | Rubraca, Eligard |
| Foundation Medicine, INC. | $16.23 | 2022 | |
| Astellas Pharma US INC | $15.74 | 2024 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrielle Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.